{"id":1060,"date":"2015-02-05T19:29:06","date_gmt":"2015-02-05T17:29:06","guid":{"rendered":"https:\/\/dev.medizone.com\/?p=1060"},"modified":"2017-09-06T11:29:46","modified_gmt":"2017-09-06T09:29:46","slug":"medizone-splendid-similarities-worldpharma-comparator-sourcing","status":"publish","type":"post","link":"https:\/\/medizone.com\/en\/medizone-splendid-similarities-worldpharma-comparator-sourcing\/","title":{"rendered":"Comparator Sourcing Medizone &#8211; Splendid similarities &#8211; WorldPharma"},"content":{"rendered":"<p><strong>Recent MEDIZONE article &#8211; WorldPharma<\/strong> &#8211; Clinical Trials Insight<\/p>\n<p>&#8220;<strong>Splendid similarities<\/strong><br \/>\nThe benefits of biosimilars have long been championed in the medical sector, but with their use set to increase in emerging economies, securing the ever-expanding cold chain becomes more important. Gerhard H\u00f6rl, managing director of Medizone, looks at how to mitigate the associated risks. &#8230;&#8221;<br \/>\n<a href=\"http:\/\/www.worldpharmaceuticals.net\/contractors\/cold-chain-storage-and-distribution\/medizone\/\" target=\"_blank\">Click here to read full MEDIZONE article &#8211; World Pharma\u00a0&#8211; Clinical Trials Insight<\/a><\/p>\n<p><a href=\"http:\/\/www.worldpharmaceuticals.net\/contractors\/cold-chain-storage-and-distribution\/medizone\/\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-medium wp-image-1061\" src=\"https:\/\/dev.medizone.com\/wp-content\/uploads\/2015\/02\/Medizone_WorldPharma-220x300.jpg\" alt=\"Medizone_WorldPharma\" width=\"220\" height=\"300\" srcset=\"https:\/\/medizone.com\/wp-content\/uploads\/2015\/02\/Medizone_WorldPharma-220x300.jpg 220w, https:\/\/medizone.com\/wp-content\/uploads\/2015\/02\/Medizone_WorldPharma.jpg 589w\" sizes=\"auto, (max-width: 220px) 100vw, 220px\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recent MEDIZONE article &#8211; WorldPharma &#8211; Clinical Trials Insight &#8220;Splendid similarities The benefits of biosimilars have long been championed in the medical sector, but with their use set to increase in emerging economies, securing the ever-expanding cold chain becomes more important. Gerhard H\u00f6rl, managing director of Medizone, looks at how to mitigate the associated risks. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[12],"tags":[],"class_list":["post-1060","post","type-post","status-publish","format-standard","hentry","category-allgemein-2"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts\/1060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/comments?post=1060"}],"version-history":[{"count":14,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts\/1060\/revisions"}],"predecessor-version":[{"id":1200,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts\/1060\/revisions\/1200"}],"wp:attachment":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/media?parent=1060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/categories?post=1060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/tags?post=1060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}